This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	V-set domain containing T cell activation inhibitor 1 (VTCN1; B7-H4)	Studies *in vitro*, in mice and in patient samples identified anti-B7-H4 single-chain variable antibody fragments (scFvs) that could help treat cancer. In ovarian cancer samples from 15 patients, B7-H4 was expressed on the surface of all samples. A screen in yeast identified scFvs that bound B7-H4, and these scFvs reversed B7-H4-mediated inhibition of donor T cell activation. In a humanized mouse model for ovarian cancer, scFvs against B7-H4 reduced tumor growth. Next steps could include testing anti-B7-H4 scFvs or antibodies in additional ovarian cancer models. *SciBX* 6(27); doi:10.1038/scibx.2013.680 Published online July 18, 2013	Patent and licensing status unavailable	Dangaj, D. *et al. Cancer Res.*; published online May 30, 2013; doi:10.1158/0008-5472.CAN-12-3457 **Contact:** Nathalie Scholler, SRI International, Menlo Park, Calif. e-mail: nathaliescholler@gmail.com